The European Commission on Tuesday picked four antibody treatments and a repurposed rheumatoid arthritis drug by Eli Lilly for an initial portfolio of preferred drugs to treat Covid-19.

The selection of drugs is part of the EU Strategy on Covid-19 Therapeutics, launched in May, to speed up EU approval and for a joint procurement plan on behalf of member states, complementing more advanced efforts on vaccines.